G1 Therapeutics to Present at 19th Annual Needham Virtual Healthcare Conference on April 14, 2020
RESEARCH TRIANGLE PARK, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company update at the 19th Annual Needham Virtual Healthcare Conference on April 14, 2020 at 2:10 p.m. ET.
To access live and archived webcasts of the presentation, please visit the of the .
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib has received Breakthrough Therapy Designation from the FDA; a rolling NDA submission for small cell lung cancer is expected to be completed in the second quarter of 2020. is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter .
Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
